Suchergebnisse - (Person:"Liu, Geoffrey")

PubPharm (22)

1

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib : Results of Phase 3 ALTA-3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Yang, J. | Liu, G. | Lu, S. | +11

2

Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis

enthalten in: Advances in therapy | 2023

von Liu, G. | Lam, V.

3

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors : Canadian Real-World Experience

enthalten in: Current oncology (Toronto, Ont.) | 2023

von Rupp, M. | Fanton-Aita, F. | Snow, S. | +11

4

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer : updated analysis of data from the phase 3, randomised, open-label CROWN study

enthalten in: The Lancet. Respiratory medicine | 2023

von Solomon, B. | Bauer, T. | Mok, T. | +15

CommentIn: Lancet Respir Med. 2023 Apr;11(4):302-304. - PMID 36535299

5

Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer

enthalten in: Clinical lung cancer | 2023

von Schmid, S. | Cheng, S. | Chotai, S. | +16

6

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib : ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Ou, S. | Nishio, M. | Ahn, M. | +20

CommentIn: J Thorac Oncol. 2023 Mar;18(3):e28-e29. - PMID 36842817

7

Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2022

von Mazieres, J. | Iadeluca, L. | Shaw, A. | +11

8

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Solomon, B. | Bauer, T. | Ignatius Ou, S. | +12

CommentIn: J Clin Oncol. 2022 Nov 1;40(31):3564-3568. - PMID 35679525

9

Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer

enthalten in: Future oncology (London, England) | 2021

von Solomon, B. | Bauer, T. | de Marinis, F. | +11

CommentOn: N Engl J Med. 2020 Nov 19;383(21):2018-2029. - PMID 33207094

10

Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)

enthalten in: Future oncology (London, England) | 2021

von Popat, S. | Liu, G. | Lu, S. | +3